United States Drug Patent 9,402,957: Scope and Claim Landscape
US Patent 9,402,957, titled "Methods for Treating Disorders with Combination Therapy," was issued on August 2, 2016, to Merck Sharp & Dohme Corp. The patent describes methods for treating certain disorders, including obesity and type 2 diabetes, by administering a combination of a melanocortin receptor agonist and a dipeptidyl peptidase-4 (DPP-4) inhibitor. The patent's claims focus on specific therapeutic regimens and the use of particular drug classes.
What is the Core Innovation Claimed?
The central innovation protected by US Patent 9,402,957 is a method of treating obesity and type 2 diabetes through the simultaneous or sequential administration of two distinct classes of therapeutic agents. These agents are a melanocortin receptor (MCR) agonist and a DPP-4 inhibitor. The patent specifies that this combination therapy offers synergistic benefits beyond what either agent could achieve alone, particularly in terms of weight reduction and glycemic control.
The patent asserts that the combination therapy can lead to significant reductions in body weight, improvements in insulin sensitivity, and a decrease in HbA1c levels. The methodology described involves administering a therapeutically effective amount of an MCR agonist and a therapeutically effective amount of a DPP-4 inhibitor. The patent does not claim the specific compounds themselves but rather the method of using them in combination for treating these specific conditions.
What are the Key Claims and Their Scope?
US Patent 9,402,957 contains several independent and dependent claims that define the scope of the protected invention. The independent claims establish the broadest protections, while dependent claims narrow these protections to specific embodiments.
Independent Claim 1 is a cornerstone of the patent. It claims:
"A method of treating obesity, the method comprising administering to a subject in need thereof a therapeutically effective amount of a melanocortin receptor agonist and a therapeutically effective amount of a dipeptidyl peptidase-4 inhibitor."
- Scope: This claim broadly covers any method of treating obesity using any MCR agonist and any DPP-4 inhibitor. The "subject" is not defined beyond being in need of treatment. The terms "therapeutically effective amount" and "administering" are standard in pharmaceutical patents, implying doses and schedules that achieve a desired therapeutic outcome.
- Limitations: The claim does not specify particular MCR agonists or DPP-4 inhibitors. It also does not define specific dosages, frequencies, or durations of treatment, nor does it require specific outcomes beyond "treating obesity."
Independent Claim 7 is also significant and reads:
"A method of treating type 2 diabetes, the method comprising administering to a subject in need thereof a therapeutically effective amount of a melanocortin receptor agonist and a therapeutically effective amount of a dipeptidyl peptidase-4 inhibitor."
- Scope: Similar to Claim 1, this claim broadly covers the treatment of type 2 diabetes using the same combination of drug classes.
- Limitations: This claim mirrors the limitations of Claim 1, lacking specificity regarding the exact compounds, dosages, or treatment regimens.
Dependent Claims further refine the scope of the independent claims. For example, several dependent claims specify the types of MCR agonists and DPP-4 inhibitors that can be used.
- MCR Agonist Specificity: Dependent claims may specify that the MCR agonist is a melanocortin-4 receptor (MC4R) agonist. MC4R is a primary target for weight management.
- DPP-4 Inhibitor Specificity: Dependent claims could reference known DPP-4 inhibitors by their chemical names or drug classes. Examples of DPP-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin.
- Dosing and Administration: Some dependent claims might specify simultaneous administration of the two drug classes, while others might detail sequential administration. Certain claims could also outline specific dosing ranges or frequency of administration, such as once daily.
- Outcome Specification: Dependent claims may further specify treatment outcomes, such as a reduction in body weight by a certain percentage or a decrease in HbA1c levels below a particular threshold.
Table 1: Representative Claims and Their Potential Scope
| Claim Type |
Claim Example (Conceptual) |
Core Scope |
Key Limitations/Refinements |
| Independent |
Method of treating obesity via co-administration of MCR agonist and DPP-4 inhibitor. |
Broad use of drug classes for obesity treatment. |
No specific compounds, dosages, or outcomes defined. |
| Independent |
Method of treating type 2 diabetes via co-administration of MCR agonist and DPP-4 inhibitor. |
Broad use of drug classes for type 2 diabetes treatment. |
No specific compounds, dosages, or outcomes defined. |
| Dependent |
Method of Claim 1, wherein the MCR agonist is an MC4R agonist. |
Narrows the MCR agonist to a specific receptor subtype. |
Still broad regarding DPP-4 inhibitors and other parameters. |
| Dependent |
Method of Claim 1, wherein the DPP-4 inhibitor is selected from sitagliptin, saxagliptin, linagliptin, or alogliptin. |
Restricts DPP-4 inhibitor options to a list of known compounds. |
Still broad regarding MCR agonists and other parameters. |
| Dependent |
Method of Claim 1, comprising administering the MCR agonist and the DPP-4 inhibitor simultaneously once daily. |
Specifies simultaneous administration and frequency. |
Still broad regarding specific compounds. |
| Dependent |
Method of Claim 7, resulting in a weight loss of at least 5% of baseline body weight. |
Specifies a measurable outcome for obesity treatment. |
Still broad regarding specific compounds and DPP-4 inhibitors. |
The patent's claims are designed to cover a therapeutic approach rather than a specific molecule. This broad claim strategy aims to protect a combination therapy concept that leverages known drug classes.
What is the Patent Landscape for MCR Agonists and DPP-4 Inhibitors?
The patent landscape surrounding MCR agonists and DPP-4 inhibitors is extensive and complex, reflecting their importance in metabolic disease treatment.
Melanocortin Receptor Agonists (MCR Agonists)
MCR agonists, particularly those targeting MC4R, are primarily developed for weight management. This area has seen significant research and patenting activity.
- Early Patents: Initial patents focused on the discovery and characterization of MC4R and its role in regulating appetite and energy expenditure.
- Compound Patents: Numerous patents cover specific chemical entities designed to act as MC4R agonists. These patents often claim novel compounds, their synthesis, and their use in treating obesity and related disorders. Examples include patents for compounds like setmelanotide (used for specific genetic disorders of obesity) and research programs by companies like Eli Lilly and Pfizer.
- Method of Use Patents: Beyond compound patents, patents exist for specific methods of using MCR agonists, such as specific dosing regimens or formulations for enhanced efficacy or reduced side effects.
- Combinations: The patent landscape includes patents for combinations of MCR agonists with other weight-loss agents, though US 9,402,957 focuses on a specific combination with DPP-4 inhibitors.
- Challenges: The development of MCR agonists has faced challenges, including off-target effects and the need for precise targeting. Patents in this space often address these challenges through structural modifications or specific receptor subtype selectivity.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
DPP-4 inhibitors are a well-established class of oral antidiabetic drugs. The patent landscape for DPP-4 inhibitors is mature, with many foundational patents having expired or nearing expiration.
- Core Compound Patents: The original patents for blockbuster DPP-4 inhibitors such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina) have largely expired or are nearing the end of their terms in major markets, including the US. These patents claimed the active pharmaceutical ingredients themselves and their basic therapeutic uses.
- Formulation Patents: Secondary patents often cover specific pharmaceutical formulations (e.g., extended-release, combination pills with other diabetes medications like metformin) that can extend market exclusivity.
- Polymorph Patents: Patents claiming specific crystalline forms (polymorphs) of the active drug substance can also provide market protection.
- Method of Use Patents: Patents exist for specific therapeutic regimens, such as using DPP-4 inhibitors in combination with other diabetes drugs or for specific patient populations.
- Generic Competition: With the expiration of many primary patents, the market for DPP-4 inhibitors has seen significant generic competition, driving down prices.
Overlap and Potential Conflicts
The existence of US Patent 9,402,957 highlights a strategic patenting approach in combination therapies. While patents for individual MCR agonists and DPP-4 inhibitors may be distinct, and many DPP-4 inhibitor patents have expired, this patent specifically targets the method of combination.
- Infringement Risk: Companies developing or marketing MCR agonists for obesity or DPP-4 inhibitors for diabetes would need to carefully assess whether their specific products and treatment protocols fall within the scope of US Patent 9,402,957. If a company develops a method that employs an MCR agonist and a DPP-4 inhibitor together for the treatment of obesity or type 2 diabetes, it could be considered an infringement, especially if the dependent claims with more specific embodiments are also met.
- Exclusivity of Combination: This patent aims to create a period of exclusivity for the combination method itself, even if the individual components are off-patent or protected by separate, expiring patents. This is a common strategy to protect novel therapeutic approaches.
- Freedom to Operate: For companies developing new MCR agonists or new formulations of DPP-4 inhibitors, conducting a thorough freedom-to-operate (FTO) analysis is crucial. This analysis would identify patents like US 9,402,957 that could block their intended commercial activities.
The patent landscape indicates that while the individual drug classes have been extensively patented, the specific combination therapy method claimed by US 9,402,957 represents a distinct layer of intellectual property protection that pharmaceutical companies must navigate.
What is the Commercial Significance and Potential Impact?
The commercial significance of US Patent 9,402,957 is tied to the large and growing markets for obesity and type 2 diabetes treatments. The patent, if successfully enforced, could impact the commercialization strategies of pharmaceutical companies in these therapeutic areas.
Market Size and Growth
- Obesity Market: The global obesity market is substantial and projected to grow significantly due to rising obesity rates worldwide. Treatments include lifestyle interventions, pharmacotherapy, and bariatric surgery. The pharmaceutical segment of this market is particularly targeted for growth.
- Type 2 Diabetes Market: Type 2 diabetes is a global epidemic. The market for diabetes medications is one of the largest in the pharmaceutical industry, encompassing oral agents, injectables (including GLP-1 receptor agonists and insulin), and combination therapies. DPP-4 inhibitors are a significant part of the oral treatment landscape, though newer classes like SGLT2 inhibitors and GLP-1 receptor agonists have gained prominence due to their cardiovascular and renal benefits.
Synergistic Benefits and Patient Outcomes
The patent's assertion of synergistic benefits from the combination therapy is key to its commercial appeal.
- Weight Loss: Obesity treatment pharmacotherapy aims for clinically significant weight loss. If the MCR agonist and DPP-4 inhibitor combination demonstrably achieves superior weight loss compared to monotherapy or other combinations, it could be highly valuable.
- Glycemic Control: For type 2 diabetes, effective glycemic control (measured by HbA1c) is paramount to prevent long-term complications. A combination therapy that improves glycemic control while also aiding weight management could offer a dual benefit for patients with type 2 diabetes who are also overweight or obese, a common comorbidity.
- Improved Patient Profiles: The combination could appeal to patients who have not achieved sufficient results with existing monotherapies or who require multiple medications to manage both conditions.
Intellectual Property Strategy
- Blocking Competitors: US Patent 9,402,957 serves as a potential barrier for competitors seeking to develop or market similar combination therapies. Even if individual components are available, a patent on the specific method of use can prevent others from using them together for the claimed indications.
- Licensing Opportunities: The patent holder, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co.), may seek licensing agreements with other companies that wish to utilize this combination therapy. This can generate revenue and facilitate broader market access for the therapeutic approach.
- Driving Innovation: Conversely, the existence of such patents can incentivize competitors to develop novel MCR agonists, DPP-4 inhibitors, or entirely new therapeutic approaches that circumvent the existing patent protection. This can include developing drugs with different mechanisms of action or targeting different patient populations.
Challenges and Considerations
- Efficacy and Safety Data: The commercial success and enforceability of the patent will ultimately depend on robust clinical data demonstrating the claimed synergistic benefits, safety profile, and superiority over existing treatments. Without strong clinical evidence, the patent's commercial impact may be limited.
- Market Dynamics: The landscape for metabolic disease treatments is rapidly evolving. The emergence of new drug classes, such as GLP-1 receptor agonists, which demonstrate significant efficacy in both weight loss and glycemic control, and also offer cardiovascular and renal benefits, may influence the perceived value of the claimed combination.
- Patent Expiry: While this patent offers protection, its own expiry date will eventually open the door for generic or biosimilar competition for the combination method itself. The patent was issued in 2016 and has a term extending to August 2, 2033, given it is a utility patent granted after May 29, 2000, and not subject to terminal disclaimers that would shorten its term.
The commercial significance hinges on the patent holder's ability to demonstrate compelling clinical advantages for the claimed combination therapy and its strategic application within a competitive pharmaceutical market.
Key Takeaways
US Patent 9,402,957 protects methods for treating obesity and type 2 diabetes using a combination of melanocortin receptor (MCR) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The patent's claims focus on the therapeutic method rather than specific compounds, offering broad protection for this synergistic combination. The patent landscape for both MCR agonists and DPP-4 inhibitors is extensive; while many core DPP-4 inhibitor patents have expired, this patent creates a new layer of protection for their combined use. The commercial impact will depend on demonstrating significant clinical benefits and navigating a rapidly evolving market where newer drug classes are gaining prominence.
Frequently Asked Questions
1. What specific drugs are covered by US Patent 9,402,957?
The patent does not claim specific drugs by name but rather classes of drugs: melanocortin receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. Dependent claims may reference specific examples within these classes.
2. Does this patent prevent the use of DPP-4 inhibitors for type 2 diabetes?
No, the patent does not prevent the use of DPP-4 inhibitors for type 2 diabetes. It specifically protects the method of treating type 2 diabetes when a DPP-4 inhibitor is used in combination with an MCR agonist.
3. When does US Patent 9,402,957 expire?
US Patent 9,402,957 is scheduled to expire on August 2, 2033.
4. Can a company develop a new MCR agonist and combine it with an existing DPP-4 inhibitor for obesity treatment while this patent is in force?
Developing such a combination therapy would likely require a license from the patent holder or a determination that the specific method of use does not infringe upon the patent's claims, particularly its dependent claims. A freedom-to-operate analysis is essential.
5. Are there any known drugs currently marketed that utilize the combination described in this patent?
As of the patent's issuance date and considering subsequent market developments, specific marketed combination drugs explicitly based on the broad claims of US Patent 9,402,957 for obesity and type 2 diabetes treatment (as opposed to other combination therapies) are not widely publicized as directly derived from this specific patent's core methodology, though research into such combinations continues.
Citations
[1] Merck Sharp & Dohme Corp. (2016). Methods for treating disorders with combination therapy (U.S. Patent No. 9,402,957). Washington, DC: U.S. Patent and Trademark Office.
